Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Efalizumab.

Manju Chacko1, Jeffrey M Weinberg

  • 1Department of Dermatology, St. Luke's-Roosevelt Hospital Center, New York, New York 10025, USA.

Dermatologic Therapy
|November 1, 2007
PubMed
Summary
This summary is machine-generated.

Efalizumab effectively treats plaque psoriasis by blocking T-cell activation and migration. It serves as a valuable first-line biologic therapy for various psoriasis types and patient groups.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Forensic dermatology and the crime scene investigation (CSI) effect: Are jurors influenced by forensic dermatologic investigations that they view on television, printed media, and the internet?

Clinics in dermatology·2026
Same author

Defining On-Treatment Remission in Plaque Psoriasis: A Consensus Statement From the National Psoriasis Foundation.

JAMA dermatology·2025
Same author

Predatory Conferences and Journals in Dermatology Are Black Widow Parties.

Skinmed·2024
Same author

Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel.

Journal of drugs in dermatology : JDD·2024
Same author

Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis Foundation.

Journal of the American Academy of Dermatology·2024
Same author

Increased risk of severe generalized pustular psoriasis due to tuberculosis screening delay for spesolimab initiation.

Journal of the American Academy of Dermatology·2023
Same journal

Increased Risk of Cutaneous T-Cell Lymphoma Development after Dupilumab Use for Atopic Dermatitis.

Dermatologic therapy·2024
Same journal

Correction to "Adjuvant PD-1 inhibitor versus high-dose interferon α-2b for Chinese patients with cutaneous and acral melanoma: A retrospective cohort analysis".

Dermatologic therapy·2022
Same journal

A case of erythema nodosum concomitant with ulcerative colitis relieved by tofacitinib.

Dermatologic therapy·2022
Same journal

A case report of vitiligo following toripalimab therapy for a patient with metastatic melanoma.

Dermatologic therapy·2022
Same journal

High versus low dose oral isotretinoin in the treatment of cutaneous and genital warts.

Dermatologic therapy·2022
Same journal

Evaluation of the efficacy and relapse rates of treatment protocols for moderate acne using isotretinoin based on the global acne grading system: Randomized, controlled, comparative study.

Dermatologic therapy·2022
See all related articles

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Efalizumab is an immunomodulator targeting T-cell pathways.
  • Approved in 2003, it treats moderate to severe chronic plaque psoriasis.

Purpose of the Study:

  • To review the efficacy and safety of efalizumab for psoriasis.
  • To highlight its clinical utility and off-label applications.

Main Methods:

  • Review of clinical efficacy and safety data.
  • Analysis of efalizumab's role in different patient populations.

Main Results:

  • Efalizumab demonstrates efficacy as a first-line biologic therapy.
  • It is effective for hand/foot psoriasis and in patients with prior TNF inhibitor failure.

Conclusions:

  • Efalizumab is a useful therapeutic option for plaque psoriasis.
  • Its utility extends to specific patient subgroups and off-label uses.